NCT00603239 - Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin | Biotech Hunter

Enrollment

165

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

exenatide

subcutaneous injection, 5 mcg or 10 mcg, twice a day (BID)

DRUG

placebo

subcutaneous injection, volume equivalent to 5 mcg or 10 mcg of active drug, twice a day

Trial Locations (25)

Research Site, Birmingham

Research Site, Concord

Research Site, Fresno

Research Site, Denver

Research Site, Las Vegas

Research Site, Mogadore

Research Site, Corvallis

Research Site, New Westminster

Research Site, Winnipeg

Research Site, Ajax

Research Site, Cambridge

Research Site, Windsor

Research Site, Chihuahua City

Research Site, Celaya

Research Site, Mexico City

Research Site, Monterrey

Research Site, Mexico City

Research Site, Baia Mare

Research Site, Brasov

Research Site, Bucharest

Research Site, Dolj

Research Site, Iași

Research Site, Suceava

Research Site, Johannesburg

Research Site, Pretoria